ARV-393

Overview

ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon , induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma. (Pink: Target protein ligand; Blue: Cereblon ligand ( HY-W039233 ); Black: linker).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Hodgkin Lymphoma | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > BCL6 | Products > Signaling Pathways > CD20 | Products > Signaling Pathways > IFNAR

Product Information

• Catalog No.: HY-158105
• CAS No.: 2851885-95-3
• Molecular Formula: C46H53ClFN9O7
• Molecular Weight: 898.42
• Purity: 99.75%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source